


253. Verslype C, Cohn AL, Kelley RK. Activity of cabozantinib (XL184) in hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-P study. J Clin Oncol 2013;31:3509–3516.


263. Vemulp C, Cohn AL, Kelley RK. Activity of caboazinostat (XL184) in hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-P study. J Clin Oncol 2013;31:3509–3516.


Chapter 52 References